학술논문

Topical treatments for early-stage mycosis fungoides using Grading Recommendations Assessment, Development and Evaluation (GRADE) criteria: A systematic review
Document Type
article
Source
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Clinical Research
Clinical Trials and Supportive Activities
5FU
topical fluorouracil
BAD
British Association of Dermatologists
CR
complete remission
GRADE
GRADE
Grading Recommendations Assessment
Development and Evaluation
MF
mycosis fungoides
NCCN
National Comprehensive Cancer Network
OFA-LP3
oxygen flow-assisted LP3 carrier
PR
partial remission
RCT
randomized
controlled
blinded trial
UK
United Kingdom
WHO-EORTC
World Health Organization-European Organisation for Research and Treatment of Cancer
corticosteroids
mycosis fungoides
nitrogen mustard
retinoids
topical treatments
Language
Abstract
BackgroundMycosis fungoides (MF) is a cutaneous lymphoma; most patients present with early, skin-limited disease and are managed by dermatologists.ObjectiveThe purpose of this study was to systematically review and assess the evidence on topical treatments for early-stage (IA, IB, IIA) MF.MethodsWe performed a literature search via MEDLINE, Embase, Web of Science, and Cochrane databases. Grading Recommendations Assessment, Development and Evaluation (GRADE) criteria were used to assess the certainty of the data.ResultsTwo searches yielded 1252 references; 26 met the inclusion criteria and included literature on nitrogen mustard, retinoids, corticosteroids, carmustine, fluorouracil, methotrexate-laurocapram, hexadecylphosphocholine, peldesine, ingenol mebutate, topical methotrexate with oxygen flow-assisted LP3 carrier, and resiquimod. Most studies were single intervention, observational series. Nitrogen mustard, with the most published reports, was effective with 12%-82% early-stage MF patients (total n > 1000) achieving complete remission (CR) (low certainty evidence). Clinical CR was achieved among 10%-60% treated with topical retinoids (low certainty evidence). Two moderate-sized retrospective case series on topical steroids had 18%-63% CR (low certainty evidence). Only single studies were available for the other therapies.ConclusionsFor most outcomes of interest, the GRADE certainty for topical therapies for early-stage MF was low. Further randomized controlled trials and inclusion of quality of life indicators are needed.